<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MAZINDOL</span><br/>(may'zin-dole)<br/><span class="topboxtradename">Mazanor, </span><span class="topboxtradename">Sanorex<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">cerebral stimulant</span>; <span class="classification">anorexiant</span><br/><b>Prototype: </b>Amphetamine Sulfate<br/><b>Pregnancy Category: </b>C<br/><b>Controlled Substance: </b>Schedule IV<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1 mg, 2 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Pharmacologic properties are similar to those of amphetamines. Produces CNS and cardiac stimulation in addition to amphetamine-like
         effects. Appears to exert primary effects on limbic system and to alter norepinephrine metabolism by inhibiting normal neuronal
         uptake mechanism.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>CNS and cardiac stimulant; also results in increased motor activity, diminished sense of fatigue, alertness, wakefulness,
         and mood elevation.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Short-term management of exogenous obesity.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Glaucoma; severe hypertension; symptomatic cardiovascular disease, including arrhythmias; agitated states; history of drug
         abuse; during or within 14 d after administration of MAO inhibitors; children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Hyperexcitability states.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Obesity</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1 mg t.i.d. a.c. or 2 mg q.d. 1 h before lunch<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Given 1 h before meals if t.i.d. or 1 h before lunch if q.d. dose.</li>
<li>Give with meals if GI discomfort occurs.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span>
<span class="speceff-common">Restlessness,</span> dizziness, insomnia, dysphoria, depression, tremor, headache, drowsiness, weakness.  <span class="typehead">CV:</span> Palpitation, tachycardia. <span class="typehead">Endocrine:</span> Impotence. <span class="typehead">GI:</span>
<span class="speceff-common">Dry mouth,</span> unpleasant taste, diarrhea, constipation, nausea, vomiting. <span class="typehead">Skin:</span> Rash, excessive sweating, clamminess. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Acetazolamide,</b>
<b>sodium bicarbonate</b> decrease mazindol elimination; <b>ammonium chloride,</b>
<b>ascorbic acid</b> increase mazindol elimination; the effects of mazindol and <span class="classification">barbiturates</span> may be antagonized; <b>furazolidone</b> may increase BP effects of mazindol, and interaction may persist for several weeks after discontinuing <b>furazolidone;</b> antihypertensive effects of <b>guanethidine,</b>
<b>guanadrel</b> antagonized; <span class="classification">mao inhibitors</span>, <b>selegiline</b> can cause hypertensive crisisdo not administer mazindol during or within 14 d of administration of these drugs; <span class="classification">phenothiazines</span> may inhibit mood elevating effects of mazindol; <span class="classification">beta-adrenergic agonists</span> increase adverse cardiovascular effects of mazindol. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Onset:</span> 3060 min. <span class="typehead">Duration:</span> 815 h. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> 95% excreted in feces, 25% in urine. <span class="typehead">Half-Life:</span> 2.59 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor weight periodically.</li>
<li>Give drug early in the day if patient experiences excessive restlessness or insomnia.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Rate of weight loss is greatest during first few weeks of therapy and tends to decrease thereafter.</li>
<li>Be aware that insulin requirements (for diabetics) may be decreased in association with mazindol.</li>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known.</li>
<li>Do not take more medication than prescribed.</li>
<li>Report excessively dry mouth or constipation.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>